Big strides in solving big human health problems! Careers @ Myeloid
In Vivo mRNA Programming
// KEY PLATFORM CHARACTERISTICS
Programming Myeloid Cells In Vivo with Novel CAR Technology
We are powering immunity through in vivo myeloid-programming.
Programming Myeloid Cells In Vivo with Novel CAR Technology
- Myeloid optimized mRNA
- Clinically-validated LNP
- In vivo validation
Cell Selectivity & Anti-Tumor Activity from Novel Fcα CAR
- Potent anti-tumor Fcα pathway
- FcRγc expressed only in target cells
- Does not require tissue-specific delivery
Versatile Platform
- Broadly applicable
- Validated targets
- Cell-specific expression
- Confirmed activity in NHP
- Proprietary manufacturing
- IND filing H1 2023
// MYELOID PROGRAMMING
Lorem Ipsum Docet
Myeloid cells are a primary orchestrator of immune response and accumulate naturally within solid tumors, in some cases representing up to seventy-five percent of the tumor mass. Myeloid’s adaptations of mRNA for the myeloid compartment have enabled delivery of these receptors directly to the patient without any ex-vivo cell engineering.
